Kamau Therapeutics, Inc.

SOUTH SAN FRANCISCO, CA · Founded 2023 · CIK 0002071165 · Biotech · Private

High-efficiency targeted gene integration platform for gene correction therapeutics

kamautx.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$5.0M
1 Form D · Jun 2025
16 months since last filing
Contracts
—
No federal contracts on record
Patents
8
0 granted · 8 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$4,999,997
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2503Exciva——
2504GYRE THERAPEUTICS, INC.—$5.0M
2505VIVOVERSE, LLC——
2506Kamau Therapeutics, Inc.—$5.0M
2507CONFLUENCE LIFE SCIENCES, INC.—$5.7M
2508Panorama Medicine Inc—$4.7M
2509GENEDIT INC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 4 related persons
  • Valentin BarsanDirector · Executive Officer
  • Ness BerminghamDirector
  • Raymond KelleherDirector
  • Matthew PorteusDirector · Executive Officer

Patents

USPTO · 0 granted of 8
  • Improved Peptide Inhibitors Of P53 Binding Protein 53BP1application
  • Methods For Genotyping Gene-edited Hematopoietic Stem Cellsapplication
  • Methods To Genetically Engineer Hematopoietic Stem And Progenitor Cells For Red Cell Specific Expression Of Therapeutic Proteinsapplication
  • Methods And Compositions For Production Of Genetically Modified Primary Cellsapplication
  • Methods And Compositions For Production Of Genetically Modified Primary Cellsapplication
  • Improved Peptide Inhibitors Of P53 Binding Protein 53BP1application
  • Methods For Clinical-scale Production Of Genetically Modified Primary Cellsapplication
  • Methods For Genotyping Gene-edited Hematopoietic Stem Cellsapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.